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Abstract
Background: The accuracy of melanoma diagnosis continues to challenge the pathology community, even today
with sophisticated histopathologic techniques. Melanocytic lesions exhibit significant morphological heterogeneity.
While the majority of biopsies can be classified as benign (nevus) or malignant (melanoma) using well-established
histopathologic criteria, there exists a cohort for which the prediction of clinical behaviour and invasive or
metastatic potential is difficult if not impossible to ascertain on the basis of morphological features alone. Multiple
studies have shown that there is significant disagreement between pathologists and even expert
dermatopathologists in the diagnosis of this subgroup of difficult melanocytic lesions.
Methods: A four probe FISH assay was utilized to analyse a cohort of 500 samples including 157 nevus, 176
dysplastic nevus and 167 melanoma specimens.
Results: Review of the lesions determined the assay identified genetic abnormalities in a total of 83.8% of
melanomas, and 1.9% of nevus without atypia, while genetic abnormalities were identified in 6.3%, 6.7%, and
10.3% of nevus identified with mild, moderate and severe atypia, respectively.
Conclusions: Based on this study, inheritable genetic damage/instability identified by FISH testing is a hallmark of
a progressive malignant process, and a valuable diagnostic tool for the identification of high risk lesions.
Background
Malignant melanoma is the seventh most common can-
cer responsible for 1-2% of all cancer related deaths [1]
with the fastest increase in incidence identified as 3-7%
per year in the United States. Cutaneous malignant mel-
anoma is a neoplasm which arises from melanocytes; it
may occur de novo, or from a pre-existing lesion such
as a congenital, acquired, or atypical (dysplastic) nevus.
Noncutaneous primary sites of melanocytes include
mucosal epithelium, retinas, and leptomeninges [2].
Melanoma is difficult to treat with therapy and most
commonly fatal if not surgically removed prior to meta-
static progression [3]. Early and accurate diagnosis of
melanoma is therefore widely regarded as the most
important factor in predicting outcome from this dis-
ease[4].
Successful management of potential melanomas is
technically challenging. The initial lesion is usually dis-
covered during either a routine physician visit, or
dermatology check-up. The “ABCD” method of physical
examination [5],A symmetry, Border irregularity, Color
variegation, and a Diameter of 6 mm or more, in con-
junction with a noticeable change over time, is typically
utilized to determine the need for an initial biopsy.
Histopathologic analysis remains the gold standard for
t h ep a t h o l o g i cd i a g n o s i so fmelanoma. Numerous cri-
teria for the histopathologic diagnosis of melanoma have
been described including asymmetry, poor circumscrip-
tion, cytologic atypia, mitotic activity, and failure of
maturation with descent [6]. Even with these criteria, a
considerable number of cases demonstrate conflicting
morphologic criteria, and several studies have shown a
level of intra-observer discordance at between 2-17%
[6,7]. As Shoo et al. (2010) demonstrated, based on
1,500,000 biopsies, and a discordance of 14.3%, this
equates to ~214,500 discordant cases in the USA
annually.
The Genetics of Melanoma
The melanocyte is a neural crest-derived cell that loca-
lizes in humans to several organs including the
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skin, melanocytes synthesize and transfer melanin pig-
ments to surrounding keratinocytes, leading to skin pig-
mentation and protection against solar exposure. The
combination of a long life cycle, constant ultraviolet
light exposure and other environmental stresses, and a
high rate of cell division coupled to replicative senes-
cence [9] categorize melanocytes as a high risk cell type
for genetic mutation and selection. Progression from
melanocyte through dysplasia, and melanoma has been
shown to be an evolutionary process requiring multiple
genetic events that subsequently affect several oncogene
and tumor suppressor pathways, which ultimately result
in increasing dysplasia, and progression to invasion, and
metastatic potential [10]. This is consistent with current
literature models in other cancer types outlining a pro-
gression from a normal cell type through dysplasia, and
finally malignancy.
The characterization of melanocytic progression to
melanoma presents specific challenges derived from the
diverse phenotypic nature of the disease. While it is gen-
erally regarded that benign nevi contain few or no
genetic alterations, and melanoma are known to possess
frequent gross genetic alterations [7] there continues to
be widespread discussion on the fundamental underlying
biology of dysplastic nevi. Central to the argument is the
contested proposition of the nature of melanocytic dys-
plasia; are a subset of dysplastic nevi premalignant
lesions of melanoma, or are all dysplastic nevi funda-
mentally benign and genetically distinct from mela-
noma? Morphologically, and phenotypically, this is
unclear as many studies have shown a wide disparity in
diagnosis even amongst experts in challenging cases
[11,12]. Current molecular studies provide convincing
evidence defining the dysplastic nevi group as a hetero-
geneous population of normal chromosomal comple-
ment; defined point mutations, and less commonly,
demonstrating a high level of chromosomal instability
and imbalance [13-16]. In contrast to this heterogeneous
nature, congenital nevi contain a normal chromosomal
complement (although “initiating” mutations in BRAF
and NRAS amongst others have been identified), while
conversely, melanoma as a group exhibits a high degree
of genetic instability with multiple gains, losses, and re-
arrangements documented [14].
Recently, Gerami et. al. (2009) [7] described a Fluores-
cent in situ hybridization (FISH) based assay for distin-
guishing this “High Risk” group of nevi, based on copy
number alterations of 3 genomic loci.. These regions
contain the known cancer oncogenes CCND1 (11q23),
MYB (6q22-q23) and RREB1 (6p25). Gerami et. al.
(2009) demonstrated that these 3 loci were found predo-
minantly in melanomas (87%), while rarely (5%) in con-
genital nevi. Significantly, a small percentage of
dysplastic nevi (5%) were also shown to harbour this
mutation. This study was able to identify a subset of aty-
pical nevi which later progressed to melanoma, and
through retrospective analysis, demonstrated that this
group of nevi harboured one or more of the CCND1,
P16 or RREB1 copy number alternations, effectively
demonstrating that atypical nevi possessing these muta-
tions have both invasive and metastatic potential.
Given the inherent difficulty in phenotypically distin-
guishing dysplastic nevi from melanoma, this paper aims
to expand on the previous studies demonstrating that
there exists a subset of melanocytic lesions for which a
confident distinction of nevi from malignant melanoma
cannot be made morphologically, but which can be
resolved through FISH analysis.
Methods
Sample Set
T h es a m p l es e tf o rt h ev a l i d ation study consisted of
samples of known melanoma, atypical nevus and benign
nevus (Table 1). All samples were obtained from three
commercial reference laboratories, and had undergone a
standard clinical diagnostic workup, including
Table 1 Sample Set: Composition by Diagnosis.
Total Cases Positive By FISH % Positive
Nevus
Congenital 8 0 0.00%
Compound 37 0 0.00%
Intradermal 62 1 1.60%
Junctional 9 0 0.00%
Mild Atypia 32 2 6.30%
Blue 9 0 0.00%
Percent Positive 1.90%
Nevus-Dysplastic
Nevus-Moderate Atypia 60 4 6.70%
Nevus-Severe Atypia 29 3 10.30%
Nevus-Scalp 38 3 7.90%
Nevus-Spitz 49 6 12.20%
Subtotal 176 Percent Positive 9.10%
Melanoma
Superficial Spreading 71 57 80.30%
Spindle cell/desmo-plastic 3 2 66.70%
Nodular 45 42 93.30%
In Situ 8 6 75.00%
Metastatic 40 33 82.50%
Subtotal 167 Percent Positive 83.80%
Total Cases 500
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special stains. Study sites were asked to provide as con-
tiguous set of samples as possible (from each of the 3
groups) to limit selection bias. Samples were removed of
all protected health information, and either blocks or
slides were shipped to the study site. All samples were
received with the original clinical diagnosis, which was
retained by the study coordinator. Samples were subse-
quently re-examined and the original diagnosis reviewed
by an internal board-certified dermatopathologist. A
small number of cases for which a conflicting diagnosis
was obtained were excluded from the validation study.
Following the internal pathology review, all samples
received an internal reference number, and the cases
were blinded to the FISH technologists.
Study Design
This study followed the standard criteria for clinical
validation of an analytical assay to the standards defined
by the appropriate accrediting agencies. The following
metrics were analyzed.
Specificity
The assay specificity was determined from the benign
nevus group. Receiver operator curve (ROC) analysis
and plots of sensitivity versus specificity were used to
independently document the relative power of each
probe set at various FISH cutoffs. Final assay cutoffs
were selected to maximize specificity over sensitivity.
Sensitivity
Sensitivity was calculated as the percentage of unambig-
uous melanoma cases defined as positive by the 4-probe
FISH assay using the derived FISH scoring cutoffs deter-
mined from the sensitivity experiment.
Atypical Positivity Rate
The percentage of nevi with moderate or severe atypia
that are scored positive using the FISH scoring cutoffs
derived from the specificity experiment were
determined.
FISH Hybridization
5 μm tissue sections were baked at 65°C for 20 min and
deparaffinized through multiple xylene washes and
dehydrated with ethanol. Specimen slides were air dried
and subsequently passed through a series of pre-treat-
ment washes on the VP2000 Processor (Abbott Molecu-
lar, Abbott Park, Illinois, U.S.A.): 1X SSC (80°C, 35
min), de-ionized (DI) water (3 min), protease solution
(10% Pepsin in 0.2N HCL; 37°C for 34 min), DI water
(3 min), increasing ethanol series (70%, 80%, 100% etha-
nol, 2 min each). The probe cocktail; MYB (6q23) in
SpectrumGold; CCND1 (11q13) in SpectrumGreen;
RREB1 (6p25) in SpectrumRed and D6Z1 (6
Centromere) in SpectrumAqua (Abbott Molecular,
Abbott Park, Illinois, U.S.A.) was manually dispensed
onto the specimen and covered with a cover glass.
Denaturation was performed on the Thermobrite
(Abbott Molecular, Abbott Park, Illinois, U.S.A) at 74°C
for 8 min followed by the hybridization at 37°C for 12-
16 hrs prior to coverslip removal. The post-hybridiza-
tion wash procedure on the VP2000 consisted of 2X
SSC with 3% Tween (70°C, 2 min) and 0.5% SSC prior
to application of DAPI counterstain and signal
enumeration.
Enumeration of FISH Signals
Slides were analysed, digitally documented, and auto-
mated probe signal enumeration performed with a Meta-
fer Slide Scanning System (MetaSystems, Waltham, MA).
The algorithm of Gerami et. al. (2009) was used for scor-
ing, with adjustments for cutoff values as described in the
discussion. All areas for automated analysis were selected
by a dermatopathologist. Alla n a l y s e sw e r ep e r f o r m e d
blinded of the specimen’s diagnoses. Tumor-bearing
areas were localized using the DAPI filter at low magnifi-
cation. The tumor area was then thoroughly inspected
for the presence of nuclei harbouring abnormal copy
numbers of any probe. Areas with the most significant
copy number changes were selected for automated enu-
meration. Wherever possible, a minimum of 3 abnormal
areas were selected and within each area 10 random
nuclei were analyzed under high-power (64× oil objec-
tive). Overlapped or poorlyh y b r i d i z e dn u c l e iw e r e
excluded from analysis. Samples in which less than 20
nuclei could be evaluated were excluded from the study.
Results
Table 2 summarizes study cohort assay results.
Discussion
Presented is an analysis of 500 cases, comprised of 157
nevi, 167 dysplastic nevi, and 176 melanoma cases. The
four-fluor FISH assay correctly identified 83.8% of mela-
nomas, and 98.1% of all benign nevi.
The four-fluor FISH panel utilized in this study identi-
fied 83.8% of true melanomas. This is consistent with
previous FISH and array comparative genomic hybridi-
zation studies, and supports the previous literature
which has clearly determined that melanomas typically
exhibit a grossly altered genetic complement. In terms
of clinical utility, the four probe panel is an effective
compromise between cost, technical complexity and
assay sensitivity. A four probe panel represents the max-
imum number of FISH probes that can be co-hybridized
to a single section. Increasing the number of probes
would increase the sensitivity, but also increase the tech-
nical complexity of the assay and associated clinical cost.
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highest sensitivity for melanoma, while the CCND1
probe and MYB probes exhibited significantly lower
sensitivities at 38% and 37% respectively. The derived
cutoff values for each probe are presented in Table 3.
Briefly, a case was considered positive if greater than
16% of scored cells for the RREB1 loci contained more
than 2 signals; or greater than 22% of CCND1contained
more than 2 signals; or more than 53% of nuclei contain
more 6p25 than centromere 6 signals; or more than 42%
of nuclei contain fewer 6q23 than centromere 6 signals.
The cutoff values presented in this study were similar,
although lower than the previously published values of
(29%, 38%, 55%, and 42% respectively) [7]. These
differences are most likely due to variation in scoring
technique, cell selection, and equipment (manual verse
automated) between the two studies. Applying the cutoff
values of Gerami et. al. (2009) to the dataset of this
study resulted in a sensitivity and specificity of 65% and
98.7% respectively (data not shown). These differences
highlight the importance of performing site specific vali-
dations for sensitivity and specificity prior to clinical
application.
Review of the benign lesions determined the assay
identified genetic abnormalities in less than 1% of nevi
without atypia (compound, junctional, congenital, and
intradermal), while genetic abnormalities were identified
in 6.3%, 6.7%, and 10.3% of nevus identified with mild,
moderate and severe atypia respectively. These results
are suggestive of a correlation between the severity of
dysplasia and an increased probability of genetic abnorm-
ality and progression to melanoma. As it is standard
practice to fully excise all dysplastic nevi, there is no
opportunity to follow this cohort to provide direct evi-
dence of morphologic progression to melanoma. While
there is insufficient evidence to confirm the absolute
malignancy of a lesion based solely on FISH analysis, the
authors agree with the previous study’s conclusions that
t h eF I S Hp o s i t i v ed y s p l a s t i cn e v ig r o u pi so fas i g n i f i -
cantly higher risk of progression to melanoma.
The assay did not identify one or more of the genetic
abnormalities in 16.2% of all confirmed melanocytic
lesions. This result infers that while these regions may be
important in pathogenesis in some melanoma, they are
clearly not causal in all melanomas. Both FISH and com-
parative genomic hybridization studies have previously
been unable to identify a single genetic marker, or set of
markers present in all samples, suggesting that the phe-
notypic representation of melanoma is actually com-
prised of several (or more) genetic “families”,e a c hw i t ha
unique underlying set of down regulated tumor suppres-
sors and activated oncogenes driving pathogenesis. Simi-
lar degrees of genetic heterogeneity has been observed
and studied in other cancers, and molecular characteriza-
tion is being utilized clinically as an adjunct to traditional
phenotypic markers to assist in diagnosis and treatment
of many cancers including invasive breast carcinoma [3],
lung cancer [17,18], prostate cancer [19], sarcomas [20],
and renal tumors [21]. In invasive carcinoma of the
breast, molecular profiling is routinely utilized in con-
junction with traditional pathology to sub classify the
tumors into molecular classes (basal-like, luminalA, lumi-
nal B, ERRBB2/Her2+), with different prognosis and dif-
ferent responses to specific therapies [3].
Conclusions
These results are consistent to the current literature
models for cancer progression, characterized by a
Table 2 Study Results.
Total Cases Positive By FISH % Positive
Nevus
Congenital 8 0 0.00%
Compound 37 0 0.00%
Intradermal 62 1 1.60%
Junctional 9 0 0.00%
Mild Atypia 32 2 6.30%
Blue 9 0 0.00%
Percent Positive 1.90%
Nevus-Dysplastic
Nevus-Moderate Atypia 60 4 6.70%
Nevus-Severe Atypia 29 3 10.30%
Nevus-Scalp 38 3 7.90%
Nevus-Spitz 49 6 12.20%
Subtotal 176 Percent Positive 9.10%
Melanoma
Superficial Spreading 71 57 80.30%
Spindle cell/desmo-plastic 3 2 66.70%
Nodular 45 42 93.30%
In Situ 8 6 75.00%
Metastatic 40 33 82.50%
Subtotal 167 Percent Positive 83.80%
Total Cases 500
Table 3 Derived Cutoff values by Probe
Loci Cutoff Value
RREB1>2 16%
CCND1>2 19%
RREB1>cen6 53%
MYB< cen6 42%
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erative progressive genetic mutations, phenotypic de-dif-
ferentiation, activation of tumor oncogenes, inhibition of
tumor suppressor genes, until the cell reaches a state of
de-differentiation where invasion and metastatic poten-
tial is possible. While the genetics behind this progres-
sion is well studied in several malignancies, there is still
significant disagreement in the melanoma community as
to the correlation (if any) between genetic instability
and phenotypic dysplasia or atypia. While there con-
tinues to be significant discussion in pathology texts on
the role of atypic presentation in the progression of mel-
anocytic nevi to melanoma, genetically, it is clear that
the process from melanocyte to melanoma requires
multiple initiating events, followed by genomic instabil-
ity, and finally progression to phenotypically evident
malignancy.
Based on these results, the four-fluor FISH assay accu-
rately identifies a molecular signature which is consis-
tent with lesions that have invasive and metastatic
potential. Lesions with these genetic qualities should be
considered as possessing a genetic signature consistent
with invasion and metastatic potential, even if this is not
evident by morphology alone.
Clinically, the utility of this assay is predicated on the
high specificity, and even in the absence of a conclusive
melanoma diagnosis, the authors believe that a positive
FISH case with corresponding atypical morphology
should be treated as a high risk lesion and may warrant
a wider excision, and more routine follow-up. Due to
the moderate sensitivity of 83.8%, care must be taken in
the analysis of dysplastic nevi which are negative by
FISH, with the inference being that almost 17% of mela-
nomas are driven by a molecular profile which is unde-
tected through this assay. Conversely, a negative FISH
result may provide additional re-assurance to the pathol-
ogist in cases where a benign result is expected, and
excision is difficult or undesired. When accompanied by
morphological risk factors, a positive FISH result is a
valuable diagnostic tool for the identification of high
risk lesions.
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